Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$5.84
-4.2%
$4.80
$1.38
$7.34
$161.15M1.51692,209 shs370,825 shs
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
$0.38
+3.4%
$0.20
$0.20
$0.75
$8.51M1.96915,302 shs13.18 million shs
Dominari Holdings Inc. stock logo
DOMH
Dominari
$5.17
-1.0%
$5.24
$0.83
$13.58
$75.69M0.61979,663 shs62,881 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.94
+2.4%
$1.86
$1.33
$2.89
$57.22M1.75412,781 shs54,235 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
-0.98%-10.83%+27.41%+112.20%+1.67%
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
0.00%+3.28%+91.49%-42.04%-78.65%
Dominari Holdings Inc. stock logo
DOMH
Dominari
-3.15%-2.43%-8.10%+19.45%+182.16%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-3.08%-3.57%+6.18%+23.53%-12.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agenus Inc. stock logo
AGEN
Agenus
3.9613 of 5 stars
3.34.00.04.60.01.70.6
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.3805 of 5 stars
0.02.00.00.00.02.50.6
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.9349 of 5 stars
3.51.00.00.00.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agenus Inc. stock logo
AGEN
Agenus
2.67
Moderate Buy$16.33179.92% Upside
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
0.00
N/AN/AN/A
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.00
N/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.00985.27% Upside

Current Analyst Ratings Breakdown

Latest CYTX, FBIO, AGEN, and DOMH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.00
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$25.00
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.00
4/30/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agenus Inc. stock logo
AGEN
Agenus
$103.46M1.55N/AN/A($13.06) per share-0.45
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
$3.67M2.32N/AN/A$0.35 per share1.10
Dominari Holdings Inc. stock logo
DOMH
Dominari
$18.15M4.17N/AN/A$5.71 per share0.91
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.67M0.99N/AN/A($0.06) per share-32.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agenus Inc. stock logo
AGEN
Agenus
-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
-$12.63MN/A0.00N/A-242.60%-272.70%-56.23%N/A
Dominari Holdings Inc. stock logo
DOMH
Dominari
-$14.70M-$4.50N/AN/A-167.73%-91.67%-77.80%8/6/2025 (Estimated)
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)

Latest CYTX, FBIO, AGEN, and DOMH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Agenus Inc. stock logo
AGEN
Agenus
-$0.78N/AN/AN/A$49.71 millionN/A
8/12/2025Q2 2025
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.31N/AN/AN/A$14.53 millionN/A
5/12/2025Q1 2025
Agenus Inc. stock logo
AGEN
Agenus
-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
N/AN/AN/AN/AN/A
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.11
0.11
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
0.39
0.46
0.30
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A
5.74
5.74
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55

Institutional Ownership

CompanyInstitutional Ownership
Agenus Inc. stock logo
AGEN
Agenus
61.46%
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
2.62%
Dominari Holdings Inc. stock logo
DOMH
Dominari
42.48%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%

Insider Ownership

CompanyInsider Ownership
Agenus Inc. stock logo
AGEN
Agenus
5.50%
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
0.66%
Dominari Holdings Inc. stock logo
DOMH
Dominari
32.98%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
27.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agenus Inc. stock logo
AGEN
Agenus
44027.42 million25.91 millionOptionable
Cytori Therapeutics Inc stock logo
CYTX
Cytori Therapeutics
3722.16 millionN/ANot Optionable
Dominari Holdings Inc. stock logo
DOMH
Dominari
414.64 million9.81 millionNot Optionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable

Recent News About These Companies

FBIO Fortress Biotech, Inc. - Seeking Alpha
New Strong Sell Stocks for May 16th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agenus stock logo

Agenus NASDAQ:AGEN

$5.84 -0.26 (-4.19%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Cytori Therapeutics stock logo

Cytori Therapeutics NASDAQ:CYTX

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Dominari stock logo

Dominari NASDAQ:DOMH

$5.17 -0.05 (-0.96%)
As of 10:37 AM Eastern

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.94 +0.05 (+2.38%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.